tbuckley/cabot-search huggingface dataset:
Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
Authors: K. Matsui, A. Yoshikawa, K. Oyama, Z. Nozaki, Y. Tanada, M. Earashi, K. Kiyohara, T. Nagata, W. Fukushima, T. Shimizu, K. Maeda
Journal: Annals of Oncology (2017)
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK
Authors: Roger Williams, Graeme Alexander, Iain Armstrong, Alastair Baker, Neeraj Bhala, Ginny Camps-Walsh, Matthew E Cramp, Simon de Lusignan, Natalie Day, Anil Dhawan, John Dillon, Colin Drummond, Jessica Dyson, Graham Foster, Ian Gilmore, Mark Hudson, Deirdre Kelly, Andrew Langford, Neil McDougall, Petra Meier, Kieran Moriarty, Philip Newsome, John O'Grady, Rachel Pryke, Liz Rolfe, Peter Rice, Harry Rutter, Nick Sheron, Alison Taylor, Jeremy Thompson, Douglas Thorburn, Julia Verne, John Wass, Andrew Yeoman
Journal: The Lancet (2017)
Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection
Authors: Patrick Starlinger, David Pereyra, Stefanie Haegele, Paul Braeuer, Lukas Oehlberger, Florian Primavesi, Andreas Kohler, Florian Offensperger, Thomas Reiberger, Arnulf Ferlitsch, Barbara Messner, Guido Beldi, Stefan Staettner, Christine Brostjan, Thomas Gruenberger
Journal: Hepatology (2017)

von Willebrand Factor (vWF) was found to mediate platelet influx during the early phase of liver regeneration in mice. Furthermore, increased vWF-antigen (vWF-Ag) levels were shown to be predictive for outcome of patients with chronic liver disease. Accordingly, we aimed to assess the relevance of perioperative vWF-Ag dynamics in terms of liver regeneration and clinical outcome in patients undergoing liver resection (LR). Accordingly, we observed that vWF-Ag and its activity-estimated by ristocetin cofactor measurement-increased immediately after induction of liver regeneration and was associated with platelet accumulation within the liver. However, a significant vWF-Ag burst was only observed in patients with unaffected postoperative liver regeneration. E-selectin, as an established marker for endothelial cell activation, was found to correlate with vWF-Ag in the liver vein after induction of liver regeneration (R = 0.535, P = 0.022). Preoperative vWF-Ag levels significantly predicted postoperative liver dysfunction (LD; N = 95; area under the curve, 0.725; P = 0.009). Furthermore, a cutoff of vWF-Ag ≥182% was defined to identify patients with a higher risk for postoperative LD or morbidity. This was confirmed within an independent mulitcenter validation cohort (N = 133). Ultimately, multivariable analysis revealed that vWF-Ag was an independent predictor of postoperative LD and morbidity.Within this study, we were able to provide evidence that an initial vWF burst is required to allow for adequate platelet accumulation and concomitant liver regeneration post-LR and might be abolished as a consequence of intrahepatic endothelial cell dysfunction. We were further able to reveal and validate the potential of preoperative vWF-antigen levels to predict poor postoperative outcome in patients undergoing LR. Despite the pathophysiological relevance of our findings, vWF-Ag seems to be a valuable tool for preoperative risk assessment in patients undergoing LR. (Hepatology 2018;67:1516-1530).
Abstract 16699: Effects of Polyethylene Glycol-20K on Post-Resuscitation Survival and Neurological Function in a Rat Model of Cardiopulmonary Resuscitation
Authors: Jin Yang, Changqing Miao, Yan Xiao, Weiping Huang, Zhangle Hu, Qinyue Guo, Xiaobo Wu, Jennifer Bradley, Mary Ann Peberdy, Joseph P Ornato, Martin Mangino, Wanchun Tang
Journal: Circulation (2017)

Introduction:  Polyethylene Glycol-20K (PEG-20K) is a hybrid cell impermeant that produces non-energy dependent water transfer in the microcirculation and improves microcirculatory flow after low flow states. Reduced cell swelling, improved myocardial function, and survival have been demonstrated in a hemorrhagic shock model. The effects of PEG-20K on survival and neurological function after cardiac arrest are unknown.   Hypothesis:  Administration of PEG-20K during CPR improves survival, and neurologic function in a rat model of cardiac arrest.   Methods:  Ventricular fibrillation was induced in 20 male Sprague-Dawley rats and left untreated for 6 min. Animals were randomized into two groups of 10: PEG-20K and control. PEG-20K (10%, 2ml) and vehicle (saline) were administered in equal amounts at the beginning of CPR by continuous intravenous infusion. Defibrillation was attempted after 8 min of CPR. Survival was recorded at 24, 48, and 72 hours after resuscitation. Neurological deficit scores were recorded at 24, 48, and 72 hours PR.   Results:  All animals were resuscitated successfully. Survival was significantly improved in animals receiving PEG-20K (p   Conclusion:  Administration of PEG-20K during CPR improves post-resuscitation survival and neurological function in a rat model of CPR.   Figure 1.:    Figure 2.:
Le renforcement de l'alerte dans la surveillance en République de Serbie : une année d'expérience
Authors: M Valenciano, I Bergeri, D Jankovic, N Milic, M Parlic, D Coulombier
Journal: Eurosurveillance (2004)

La Republique de Serbie, avec le soutien de l'OMS, a mis en place un systeme d'alerte (ALERT) pour les maladies transmissibles prioritaires, en complement du systeme de surveillance de routine qui notifie les cas confirmes individuels. Cet article decrit les resultats de l'evaluation menee un an apres le lancement du programme. ALERT est base sur la declaration de 11 syndromes par les centres de soins primaires. Les donnees sont analysees sur une base hebdomadaire dans chaque region et transmises aux epidemiologistes nationaux. ALERT est percu comme un outil simple et flexible, mieux accepte au niveau national que regional. Certaines regions percoivent ALERT comme un systeme parallele insuffisamment relie aux mesures de controle. La sensibilite du systeme pour la detection des cas de meningite est de 93%, et de 37% pour les cas d'hepatite. L'analyse retrospective des donnees d'ALERT a permis d'identifier neuf epidemies, dont cinq avaient ete identifiees par les epidemiologistes. ALERT a ete le systeme le plus rapide pour la detection de quatre epidemies identifiees par les deux systemes. Le systeme ALERT a permis de declencher une investigation rapide et de controler des epidemies a hantavirus et a salmonelloses, ainsi que pour detecter le debut de la saison grippale. Cependant, ALERT n'a pas detecte des foyers de brucellose et de tularemie reperes par un syndrome de fievre inexplique. Cette evaluation a souligne le besoin d'une vue globale des activites de surveillance pour la mise en place de nouveaux systemes comme ALERT. Alors que les mesures de controle basees sur la declaration de cas confirmes individuels sont bien comprises et mises en place, le processus d'investigation et de verification qui devrait etre enclenche lors d'une augmentation des syndromes d'ALERT n'est pas parfaitement compris. Les programmes de formation a l'epidemiologie de terrain, tels que EPIET, sont les mieux adaptes pour apporter ce changement de perspective.
Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
Authors: Ryan M. Van Wagoner, Amy Eichner, Shalender Bhasin, Patricia A. Deuster, Daniel Eichner
Journal: JAMA (2017)

Recent reports have described the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approved by the US Food and Drug Administration (FDA), to enhance appearance and performance. The composition and purity of such products is not known.To determine the chemical identity and the amounts of ingredients in dietary supplements and products marketed and sold through the internet as selective androgen receptor modulators and compare the analyzed contents with product labels.Web-based searches were performed from February 18, 2016, to March 25, 2016, using the Google search engine on the Chrome and Internet Explorer web browsers to identify suppliers selling selective androgen receptor modulators. The products were purchased and the identities of the compounds and their amounts were determined from April to August 2016 using chain-of-custody and World Anti-Doping Association-approved analytical procedures. Analytical findings were compared against the label information.Products marketed and sold as selective androgen receptor modulators.Chemical identities and the amount of ingredients in each product marketed and sold as selective androgen receptor modulators.Among 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or Andarine). An additional 17 products (39%) contained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Of the 44 tested products, no active compound was detected in 4 (9%) and substances not listed on the label were contained in 11 (25%). In only 18 of the 44 products (41%), the amount of active compound in the product matched that listed on the label. The amount of the compounds listed on the label differed substantially from that found by analysis in 26 of 44 products (59%).In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances. Only 52% contained selective androgen receptor modulators and many were inaccurately labeled.
Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study
Authors: Filip Mejza, Louisa Gnatiuc, A. Sonia Buist, William M. Vollmer, Bernd Lamprecht, Daniel O. Obaseki, Pawel Nastalek, Ewa Nizankowska-Mogilnicka, Peter G.J. Burney
Journal: European Respiratory Journal (2017)

We studied the prevalence, burden and potential risk factors for chronic bronchitis symptoms in the Burden of Obstructive Lung Disease study. Representative population-based samples of adults aged ≥40 years were selected in participating sites. Participants completed questionnaires and spirometry. Chronic bronchitis symptoms were defined as chronic cough and phlegm on most days for ≥3 months each year for ≥2 years. Data from 24 855 subjects from 33 sites in 29 countries were analysed. There were significant differences in the prevalence of self-reported symptoms meeting our definition of chronic bronchitis across sites, from 10.8% in Lexington (KY, USA), to 0% in Ile-Ife (Nigeria) and Blantyre (Malawi). Older age, less education, current smoking, occupational exposure to fumes, self-reported diagnosis of asthma or lung cancer and family history of chronic lung disease were all associated with increased risk of chronic bronchitis. Chronic bronchitis symptoms were associated with worse lung function, more dyspnoea, increased risk of respiratory exacerbations and reduced quality of life, independent of the presence of other lung diseases. The prevalence of chronic bronchitis symptoms varied widely across the studied sites. Chronic bronchitis symptoms were associated with significant burden both in individuals with chronic airflow obstruction and those with normal lung function.
Time to Appendectomy and Risk of Complicated Appendicitis and Adverse Outcomes in Children
Authors: William Bonadio
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Exploring the association between <i>KRAS</i> mutations and depression in non-small cell lung cancer (NSCLC) patients.
Authors: Jenny Jing Li, Jessica Harper, Nizar Bhulani, David E. Gerber, Saad A. Khan, Alejandra Madrigales, Samantha Gates, Marisa Toups, Muhammad Shaalan Beg
Journal: Journal of Clinical Oncology (2017)

114 Background: Previous studies have demonstrated a higher rate of depression in cancer patients harboring KRAS mutations. We evaluated the feasibility of using secondary Electronic Medical Record (EMR) data to examine the association of KRAS mutations with depression in NSCLC patients. Methods: We identified cases with NSCLC from an institutional Cancer Registry. Tumor molecular profiles were obtained as standard of care. Depression was assessed using the Patient Health Questionnaire-2 (PHQ-2), which is part of the institution’s universal Distress Screening tool completed at the time of clinic visit. PHQ-2 score of 2 and above was considered positive for depression. Data was extracted from EMR via Clinical Data Exchange Network bioinformatics tool and confirmed by chart review. Results: Of the 692 NSCLC patients, KRAS status was known in 174 cases: 40 (23%) were KRAS mutated and 134 (77%) were KRAS wild type. 101 (58%) had stage 4 NSCLC. PHQ-2 score was 0 in 146 (83.9%), 1 in 7 (4%), 2 in 19 (10.9%), and &gt; 2 in 2 (1.1%). The rate of positive PHQ-2 for KRAS mutated vs wild type was 15% vs 11% (p = NS). Conclusions: This study in patients with NSCLC did not demonstrate an association between KRAS mutation and depression. Bioinformatics studies harnessing EMR data are a feasible platform to assess the association of genomic data with clinical outcomes and validated algorithms are needed.
Biological Cleavage of the C–P Bond in Perfluoroalkyl Phosphinic Acids in Male Sprague-Dawley Rats and the Formation of Persistent and Reactive Metabolites
Authors: Shira Joudan, Leo W.Y. Yeung, Scott A. Mabury
Journal: Environmental Health Perspectives (2017)

Background: Perfluoroalkyl phosphinic acids (PFPiAs) have been detected in humans, wildlife, and various environmental matrices. These compounds have been used with perfluoroalkyl phosphonic acids (PFPAs) as surfactants in consumer products and as nonfoaming additives in pesticide formulations. Unlike the structurally related perfluoroalkyl sulfonic and carboxylic acids, little is known about the biological fate of PFPiAs. Objectives: We determined the biotransformation products of PFPiAs and some pharmacokinetic parameters in a rat model. Methods: Male Sprague-Dawley rats received an oral gavage dose of either C6/C8PFPiA, C8/C8PFPiA, or C8PFPA. Blood was sampled over time, and livers were harvested upon sacrifice. Analytes were quantified using ultra-high-performance liquid chromatography–tandem mass spectrometry or gas chromatography–mass spectrometry. Results: PFPiAs were metabolized to the corresponding PFPAs and 1H-perfluoroalkanes (1H-PFAs), with 70% and 75% biotransformation 2 wk after a single bolus dose for C6/C8PFPiA and C8/C8PFPiA, respectively. This is the first reported cleavage of a C-P bond in mammals, and the first attempt, with a single-dose exposure, to characterize the degradation of any perfluoroalkyl acid. Elimination half-lives were 1.9±0.5 and 2.8±0.8 days for C6/C8PFPiA and C8/C8PFPiA, respectively, and 0.95±0.17 days for C8PFPA. Although elimination half-lives were not determined for 1H-PFAs, concentrations were higher than the corresponding PFPAs 48 h after rats were dosed with PFPiAs, suggestive of slower elimination. Conclusions: PFPiAs were metabolized in Sprague-Dawley rats to form persistent PFPAs as well as 1H-PFAs, which contain a labile hydrogen that may undergo further metabolism. These results in rats produced preliminary findings of the pharmacokinetics and metabolism of PFPiAs, which should be further investigated in humans. If there is a parallel between the disposition of these chemicals in humans and rats, then humans with detectable amounts of PFPiAs in their blood may be undergoing continuous exposure. https://doi.org/10.1289/EHP1841
Cisplatin substitution with carboplatin during radical chemoradiation (CRT) for localised gastroesophageal carcinoma (GEC): Outcomes from a tertiary referral centre
Authors: A. Athauda, D. Watkins, K. Mohammed, A. Ramessur, I. Chau, N. Starling, S. Rao, D. Tait, K. Aitken, N. van As, D. Cunningham
Journal: Annals of Oncology (2017)
Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study
Authors: Olivier Marcy, Mathurin Tejiokem, Philippe Msellati, Khanh Truong Huu, Viet Do Chau, Duong Tran Ngoc, Boubacar Nacro, Francis Ateba-Ndongo, Suzie Tetang-Ndiang, Vibol Ung, Bunnet Dim, Leakhena Neou, Laureline Berteloot, Laurence Borand, Christophe Delacourt, Stéphane Blanche, Sao Sarady Ay, Laurence Borand, Malen Chan, Phalla Chea, Bunnet Dim, Sophie Goyet, Olivier Marcy, Nimul Roat Men, Phearavin Pheng, Susan Ramsay, Sophea Suom, Arnaud Tarantola, Naisim Te, Sreymom Than, Sovannary Ung, Chorn Chhuk, Chantheany Huot, Sang Han Kath, Sokoeun Khin, Peou Kim, Kim Eng Lim, Phary Lim, Vannareth Lim, Yany Nav, Boren Pich, Sotharin Tuy, Vibol Ung, Phal Chea, Sengtray Chhraing, Bophal Chuop, Ramy Hem, Phanoeurn Heng, Seng Hap Huon, Sokhorn Khum, Thear Liv, Vichea Ly, Makara Moch, Leakheana Neou, Phanith Rey, Vina Sath, Nopheavann Sun, Pheron Chat, Viso Srey, Sitha Chheang, Putchhat Hor, Manory Oum, Monorea Keo, Sokchea Kou, Sokleaph Cheng, Alexandra Kerleguer, Michel Gomgnimbou, Antoinette Kabore, Anselme Millogo, Boubacar Nacro, Zakari Nikiema, Abdul Salam Ouedraogo, Sawadogo Saidou, Moumini Nouctara, Diane Ursule Sangare/Ouattara, Bintou Sanogo, Edgard Sib Sié, Dézémon Zingué, Roger Ngoya Abiguide, Patrice Assene Ngo'o, Francis Ateba Ndongo, Suzanne Balla, Verlaine Bolyse Mbouchong, Jean Marie Ehongo Amanya, Sara Eyangoh, Afi Leslie Kaiyven, Paul Koki Ndombo, Samuel Walter Kokola Bayanak, Marie Josée Mapah Kampaing, Elizabeth Mangoya, Minkala Mvogo, Jean Pierre Ndongo, Laurence Ngassam, Francine Nanda, Sylviane Ndjantou, Jean Audrey Ndongo, Marcelle Njind Nkoum, Anne Esther Njom Lend, Angeline Nkembe, Marie Flore Oyanche, Jean-Voisin Taguebue, Mathurin Tejiokem, Suzy Tetang-Moyo, Sylvie Georgette Zebaze, Thi Oanh Nguyen, Thi Ngoc Lan Nguyen, Catherine Quillet, Khanh Lê Quoc, My Huong To, Thi Kim Phung Tran, Chau Giang Do, Duc Bang Nguyen, Ngo Vi Vi Nguyen, Thi Hieu Nguyen, Thi Thanh Thanh Nguyen, Ngoc Duong Tran, Duy An Vo, Thi Xuan Lan Dang, Thi Kim Phuong Do, Thi Thanh Tuyen Dang, Hoang Chau Nguyen, Ngoc Tuong Vy Pham, Huu Khanh Truong, Chau Viet Do, Bich Ngoc Huynh, Thi Thanh Thuy Le, Thi Thu Hiep Nguyen, Ngoc Luu Tran, Thien An Vu, Huu Loc Tran, Manh Hoang Nguyen, Ngoc Lan Nguyen, Thi Cao Van Nguyen, Thu Hang Pham, Dinh Quyen Phan, Thi Ha Vo, Xuan Lien Truong, Xuan Thinh Vu, Stéphane Blanche, Christophe Delacourt, Laureline Berteloot, Guislaine Carcelain, Sylvain Godreuil, Isabelle Fournier-Nicolle
Journal: The Lancet HIV (2017)
Map of DNA Sites Governing Gene Expression Finalized
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum to:Dynamics of gene silencing during X inactivation using allele-specific RNA-seq (vol 16, 149, 2015)
Authors: H. Marks, H.H.D. Kerstens, T.S. Barakat, E. Splinter, R.A.M. Dirks, G. van Mierlo, O.K. Joshi, S. Wang, T. Babak, C.A. Albers, T. Kalkan, A. Smith, A. Jouneau, W. de Laat, J. Gribnau, H.G. Stunnenberg
Journal: Genome biology (2016)
Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy
Authors: S.C. Lee, S-C Chen, M-S Dai, G.E. Lee, C-L Liu, A. Chan, H-K Chang, L-M Tseng, W.Y. Chay, L.W.C. Chow, J.L. Peneyra, K-M Rau, H-C Wang, A.A. Guancia, M. Head, J.W.Y. Chiu, B. Robinson, B. Lindmark, N. McIntyre, C-Y Hsieh
Journal: Annals of Oncology (2017)
A prospective observational study of immune checkpoint inhibitor nivolumab treatment in patients with non-small cell lung cancer
Authors: T. Fukui, Y. Nakahara, S. Otani, M. Katagiri, H. Mitsufuji, M. Kubota, Y. Hiyoshi, M. Ishihara, M. Kasajima, S. Igawa, J. Sasaki
Journal: Annals of Oncology (2017)
Editorial: Wnt Signaling Related to Subchondral Bone Density and Cartilage Degradation in Osteoarthritis
Authors: David B. Burr, Achint Utreja
Journal: Arthritis & Rheumatology (2017)

The role of subchondral bone in the progression of osteoarthritis has been controversial for nearly 50 years. (1,2)The observation that subchondral sclerosis was nearly always present in end-stage disease led to the conclusion that the increased stiffness caused by a thicker subchondral bone plate detracted from the bone's ability to attenuate the loads imposed on the joint cartilage, increasing cartilage stresses and initiating the process of joint deterioration.Because cartilage damage does not always progress to full thickness cartilage loss and OA, Radin and Rose (3) proposed that the initiation and the progression of cartilage deterioration were separate processes.They suggested that it was steep stiffness gradients at the joint margins, primarily regions of high tensile and shear stresses that create inhomogeneities in the subchondral plate/cartilage complex.They hypothesized that these changes caused differential deformation between more compliant and denser regions of the subchondral bone, tearing the cartilage attached to it and initiating fibrillation.They further proposed that progression of cartilage loss, a separate process, ensued when continued